SITIME Corp (SITM): auditor change — SiTime restates cash flow statements for Q1-Q3 2023; material weakness identified

SITIME Corp

Interest received on held-to-maturity securities misclassified as investing activity instead of operating; no impact on cash balance, income, or equity.
Restatement affects Q1, Q2, and Q3 2023 quarterly reports; adjustments range from $4.4M to $18.4M across periods.
Management and audit committee deem previously issued cash flow statements no longer reliable as of Jan 22, 2024.
Material weakness in internal control over financial reporting identified for all three quarters; remediation plan to follow.
Amendments to Form 10-Qs for Q1-Q3 2023 will be filed to correct the misclassification.

item 4.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

SITIME Corp reported that prior financial statements should not be relied upon.

Action: non reliance

Exact text from the filing

On January 22, 2024, management and the audit committee of the board of directors of the Company concluded that, as a result of the Misclassification and in accordance with, Staff Accounting Bulletin No. 99, “Materiality,” the consolidated statements of cash flows in the first three quarters of 2023 were materially misstated and that the Company’s previously issued unaudited financial statements in the Quarterly Reports on Form 10-Q for the periods ended March 31, 2023, June 30, 2023, and September 30, 2023, should no longer be relied upon due to the Misclassification.

View on SEC.gov

8 auditor changes filed in the last 30 days. Browse all auditor changes →

SITIME Corp filing history →

Source: SEC EDGAR

accession 0001451809-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.